{"title":"聚焦超声治疗宫颈人乳头瘤病毒感染和鳞状上皮内病变:叙述综述","authors":"Vincent Y.T. Cheung","doi":"10.1016/j.eurox.2025.100406","DOIUrl":null,"url":null,"abstract":"<div><div>Focused ultrasound (FUS) appears to be a promising form of thermal ablation for treatment of cervical lesions, but evidence supporting its use is limited. This review evaluated the efficacy and safety of FUS treatment of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL). The overall efficacy of FUS on HPV clearance was 75.0–85.7 % at 3 months, 35.5–77.1 % at 6 months and 64.7–94.1 % at 12 months. Its efficacy on low grade SIL and high grade SIL regression were 83.3–96.8 % and 70.9–96.6 % at 6 months, respectively. Complications were uncommon. FUS appears to be an effective and safe treatment modality for cervical HPV and SIL.</div></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":"26 ","pages":"Article 100406"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Focused ultrasound treatment of cervical human papillomavirus infection and squamous intraepithelial lesions: A narrative review\",\"authors\":\"Vincent Y.T. Cheung\",\"doi\":\"10.1016/j.eurox.2025.100406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Focused ultrasound (FUS) appears to be a promising form of thermal ablation for treatment of cervical lesions, but evidence supporting its use is limited. This review evaluated the efficacy and safety of FUS treatment of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL). The overall efficacy of FUS on HPV clearance was 75.0–85.7 % at 3 months, 35.5–77.1 % at 6 months and 64.7–94.1 % at 12 months. Its efficacy on low grade SIL and high grade SIL regression were 83.3–96.8 % and 70.9–96.6 % at 6 months, respectively. Complications were uncommon. FUS appears to be an effective and safe treatment modality for cervical HPV and SIL.</div></div>\",\"PeriodicalId\":37085,\"journal\":{\"name\":\"European Journal of Obstetrics and Gynecology and Reproductive Biology: X\",\"volume\":\"26 \",\"pages\":\"Article 100406\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Obstetrics and Gynecology and Reproductive Biology: X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590161325000420\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590161325000420","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Focused ultrasound treatment of cervical human papillomavirus infection and squamous intraepithelial lesions: A narrative review
Focused ultrasound (FUS) appears to be a promising form of thermal ablation for treatment of cervical lesions, but evidence supporting its use is limited. This review evaluated the efficacy and safety of FUS treatment of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL). The overall efficacy of FUS on HPV clearance was 75.0–85.7 % at 3 months, 35.5–77.1 % at 6 months and 64.7–94.1 % at 12 months. Its efficacy on low grade SIL and high grade SIL regression were 83.3–96.8 % and 70.9–96.6 % at 6 months, respectively. Complications were uncommon. FUS appears to be an effective and safe treatment modality for cervical HPV and SIL.